Smartphone Screen Testing, a novel pre-diagnostic method to identify SARS-CoV-2 infectious individuals
- Institute of Ophthalmology, UCL, United Kingdom
- Diagnosis Biotech, Chile
- Grupo Oncológico Cooperativo Chileno de Investigación, Chile
- Clínica Dávila, Chile
- Clinica Davila, Chile
- University of Chile, Chile
- Faculty of Chemistry and Biology, University of Santiago of Chile, Chile
- Great Ormond Street Hospital National Health Service Foundation Trust, Chile
Abstract
The COVID-19 pandemic will likely take years to control globally, and constant epidemic surveillance will be required to limit the spread of SARS-CoV-2, especially considering the emergence of new variants that could hamper the effect of vaccination efforts. We developed a simple and robust - Phone Screen Testing (PoST) - method to detect positive SARS-CoV-2 individuals by RT-PCR testing of smartphone screen swab samples. We show that 81.3-100% of individuals with high-viral load SARS-CoV-2 nasopharyngeal positive samples also test positive for PoST, suggesting this method is effective in identifying COVID-19 contagious individuals. Furthermore, we successfully identified polymorphisms associated with SARS-CoV-2 Alpha, Beta and Gamma variants, in SARS-CoV-2 positive PoST samples. Overall, we report that PoST is a new non-invasive, cost-effective, and easy to implement smartphone-based smart alternative for SARS-CoV-2 testing, which could help to contain COVID-19 outbreaks and identification of variants of concern in the years to come.
Data availability
All the data used generated by this study was provided in the uploaded manuscript and source files.
Article and author information
Author details
Funding
Moorfields Eye Charity (Career Development Award 001155)
- Rodrigo M Young
Moorfields Eye Charity (Springboard Award GR001210)
- Rodrigo M Young
Agencia Nacional de Investigacion y Desarrollo Chile (ANID-Covid0789)
- Luis A Quiñones
Agencia Nacional de Investigacion y Desarrollo Chile (ANID-Covid1038)
- Ana M Sandino
Agencia Nacional de Investigacion y Desarrollo Chile (ANID-Covid1038)
- Ana M Sandino
Fondecyt (1211841)
- Felipe Reyes-Lopez
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Human subjects: Informed consent and consent to publish was obtained from all the individuals that participated in this study before performing the sampling process. This has been made explicit in the materials and methods section of the article. Ethical approval was obtained by the Ethics and Scientific Committee of Clinica Davila (Santiago, Chile) under the approval titled: "Identificación de marcadores de riesgo asociados a la severidad del Covid-19 en el microbioma respiratorio".
Copyright
© 2021, Young et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 7,471
- views
-
- 479
- downloads
-
- 9
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Smartphone Screen Testing, a novel pre-diagnostic method to identify SARS-CoV-2 infectious individuals
eLife 10:e70333.
https://doi.org/10.7554/eLife.70333
Further reading
-
Mobile phones could be used to test for COVID-19
-
- Microbiology and Infectious Disease
Infection with the protozoan parasite Trypanosoma cruzi is generally well-controlled by host immune responses, but appears to be rarely eliminated. The resulting persistent, low-level infection results in cumulative tissue damage with the greatest impact generally in the heart in the form of chagasic cardiomyopathy. The relative success in immune control of T. cruzi infection usually averts acute phase death but has the negative consequence that the low-level presence of T. cruzi in hosts is challenging to detect unequivocally. Thus, it is difficult to identify those who are actively infected and, as well, problematic to gauge the impact of treatment, particularly in the evaluation of the relative efficacy of new drugs. In this study, we employ DNA fragmentation and high numbers of replicate PCR reaction (‘deep-sampling’) and to extend the quantitative range of detecting T. cruzi in blood by at least three orders of magnitude relative to current protocols. When combined with sampling blood at multiple time points, deep sampling of fragmented DNA allowed for detection of T. cruzi in all infected hosts in multiple host species, including humans, macaques, and dogs. In addition, we provide evidence for a number of characteristics not previously rigorously quantified in the population of hosts with naturally acquired T. cruzi infection, including, a >6 log variation between chronically infected individuals in the stable parasite levels, a continuing decline in parasite load during the second and third years of infection in some hosts, and the potential for parasite load to change dramatically when health conditions change. Although requiring strict adherence to contamination–prevention protocols and significant resources, deep-sampling PCR provides an important new tool for assessing therapies and for addressing long-standing questions in T. cruzi infection and Chagas disease.
